Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283491 | 0.83 | PDK2 (0.34) | PDK2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL27788557 | 0.79 | MAPK1 (0.38) | MAPK1SMN1; SMN2 | |
| SCHEMBL26860416 | 0.77 | HTR2A (0.33) | — | |
| SCHEMBL28207346 | 0.75 | THRB (0.40) | — | |
| SCHEMBL26860421 | 0.74 | HTR2A (0.31) | PDK2 | |
| SCHEMBL5613460 | 0.74 | HTR2A (0.31) | — | |
| Methane SCHEMBL7908635 | 0.72 | MAPK1 (0.36) | PDK2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL15642615 | 0.72 | MAPK1 (0.36) | PDK2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL15686142 | 0.72 | MAPK1 (0.36) | PDK2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL30638044 | 0.72 | HTR2A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010613-A1 | NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN | MERCK SHARP & DOHME LLC (US) | 2024-01-11 | — | — | US | claimed |
| US-20240010613-A1 | NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN | MERCK SHARP & DOHME LLC (US) | 2024-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010613-A1 | NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN | HIF1AN, VHL, HIF1A | PDK2 347/4885MAPK1 1257/4885SMN1; SMN2 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.